Industries
Nuclear Medicine and Radiopharmaceuticals
Nuclear medicine uses radioactive isotopes attached to targeting molecules for diagnosis via PET and SPECT and therapy through targeted radionuclide therapy of cancer and neurological disease. University radiochemistry and medical physics departments develop new chelation chemistries, targeting peptides, and radiolabeling automation platforms that companies license for clinical radiopharmaceutical pipelines.
Details
- Companies
- GE Healthcare RadiopharmaceuticalsLantheus HoldingsBracco ImagingPOINT BiopharmaRayzeBio BMSRadioMedixCurium PharmaITM Isotope TechnologiesIONETIXBlue Earth Diagnostics
- Market Size
- $6.8B
- Target Researchers
- Radiochemists, nuclear medicine physicians, and medicinal chemists specializing in radiolabeling of targeting vectors, PET tracer design, radiopharmaceutical synthesis automation, SPECT/PET imaging biomarker validation, and targeted radionuclide therapy
- Use Cases
- PET tracer precursor supplyNovel radionuclide-chelator licensingRadiopharmaceutical synthesis automationAlpha and beta-emitter radionuclide sourcingTumor-targeting vector co-developmentGMP radiolabeling CRO services